Company intelligence / Profile preview

development

Miami, Florida, USA

Ownership: Private
Development stage: Other

Overview

Developmental Therapeutics, Inc. (DTI) was a clinical-stage biotechnology company focused on the development of novel cardiovascular and metabolic therapies. The company's lead program was DITPA (3,5-diiodothyropropionic acid), an orally active thyroid hormone analog designed to improve cardiac function in patients with congestive heart failure without the typical systemic side effects of thyroid hormones. DTI was founded by Steve Kanzer and Nicholas Stergis and operated as a private entity until its acquisition. In October 2003, the company was acquired by Titan Pharmaceuticals to advance its clinical pipeline.

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

University of Arizona

Beyond the preview

Go deeper on development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on development.

Explore the full profile